The total operating income grew 50.5 per cent to Rs 2,881 cr during the quarter under review
Hyderabad, November 2014
“The quarterly performance has been satisfactory mainly on account of overall growth led by the US generics. Our business deliveries in Europe as well as other markets have been in line with our expectation. We are confident of sustaining this performance as we continue to focus on complex molecules and differentiated technology platforms for advanced markets,” said N Govindarajan, managing director of Aurobindo.
While the US contributed Rs 1,174.3 crore to Aurobindo’s sales in Q2 of FY15, as against Rs 730.8 crore in the corresponding quarter last year, Europe accounted for Rs 766.5 crore (Rs 170.6 crore in Q2 of FY14).
During the second quarter ended September 2014, Aurobindo filed two abbreviated new drug applications (ANDAs) and two drug master files (DMFs) in the US. Business Standard